Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Convatec Group's Total Liabilities for the quarter that ended in Jun. 2026 was €2,046 Mil. Convatec Group's Total Assets for the quarter that ended in Jun. 2026 was €3,286 Mil.
Therefore, Convatec Group's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.62.
Convatec Group (FRA:2CV) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Convatec Group Liabilities-to-Assets Related Terms
Convatec Group Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Convatec Group's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CV vs ISRG, BDX, MDLN: Liabilities-to-Assets Comparison
For the Medical Instruments & Supplies subindustry, Convatec Group's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Convatec Group's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Convatec Group's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group (FRA:2CV) has a Liabilities-to-Assets of 0.62 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Convatec Group and its competitors.
Is Convatec Group's Liabilities-to-Assets too high?
Convatec Group's current Liabilities-to-Assets is 0.62. Overall, Convatec Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's Liabilities-to-Assets compare to ISRG and BDX?
Convatec Group's Liabilities-to-Assets of 0.62 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Convatec Group and its competitors. Convatec Group's current Liabilities-to-Assets is 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Convatec Group (FRA:2CV) has a current Liabilities-to-Assets of 0.62. The stock's GF Value™ is €2.93, compared to a current price of €2.62 — trading 10.6% below its estimated fair value. The current Liabilities-to-Assets is 0.62. Convatec Group's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Convatec Group (FRA:2CV), the current Liabilities-to-Assets is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (FRA:2CV) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of €2.62 is trading 10.6% below its estimated GF Value™ of €2.93.
Key valuation signals for FRA:2CV:
Liabilities-to-Assets: 0.62
GF Value™: €2.93 vs. price of €2.62 (10.6% below fair value)
No single metric tells the full story. See the FRA:2CV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
82GF Score
Get the complete analysis for FRA:2CV
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CV has been successfully added to your 
